

REPLACED BY
ANT GUM

WO 2004/050121

PCT/EP2003/050891

Claims

1. A pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s).
2. The pharmaceutical composition of claim 1, wherein antiflocculant and/or antisedimentation agent is xanthan gum.
3. The pharmaceutical composition of claims 1 and 2, wherein antiflocculant and /or antisedimentation agent is combination of xanthan gum and maltodextrin.
4. The pharmaceutical composition of claims 1 to 3 further comprising a buffering agent.
5. The pharmaceutical composition of claims 1 to 4 in a dried form.
6. The pharmaceutical composition of claims 1 to 4 in a freeze-dried form.
7. The pharmaceutical composition of claims 1 to 6, wherein the cell lysate is a keratinocyte cell lysate.
8. The pharmaceutical composition of claims 1 to 7, wherein said composition further comprises a pharmaceutically acceptable carrier/excipient/vehicle.
9. The pharmaceutical composition of claims 1 to 8 for the purpose of promoting wound healing, wherein said composition comprises a non-viable cell lysate and a pharmaceutically acceptable vehicle.
10. The pharmaceutical composition of claims 8 and 9, wherein said pharmaceutically acceptable vehicle is a dry powder, a suspension or a solution.
11. The pharmaceutical composition of claims 8 and 9, wherein said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix.
12. A process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture.
13. A process of claim 12 wherein drying the cells is by freeze-drying.
14. A process of claims 12 and 13, wherein cell the lysate is a keratinocyte cell lysate.
15. A process of claims 12 to 14, wherein the antiflocculant/antisedimentation agent is xanthan gum.
16. A process of claim 12 to 15 wherein the antiflocculant and/or antisendimentation agent is a combination of xanthan gum and maltodextrin.

17. Use of the composition of claim 1 to 11 for the treatment of burn wounds or skin ulcers.